

Coast Financial Holding Inc. In certain circumstances.

Board of Governors of the Federal Reserve System, August 24, 2007.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. E7-17142 Filed 8-29-07; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 25, 2007.

**A. Federal Reserve Bank of Philadelphia** (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521:

1. *Harleysville National Corporation*, Harleysville, Pennsylvania; to retain 19.9 percent of the voting shares of Berkshire Bancorp, Inc., and thereby indirectly retain voting shares of Berkshire Bank, both of Wyomissing, Pennsylvania.

**B. Federal Reserve Bank of Cleveland** (Douglas A. Banks, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. *PNC Financial Services Group, Inc.*, Pittsburgh, Pennsylvania; to merge with Yardville National Bancorp, Hamilton, New Jersey, and thereby indirectly acquire 100 percent of Yardville National Bank, Yardville, New Jersey, and 19.9 percent of the voting shares of Bucks County Bank, Doylestown, Pennsylvania.

Board of Governors of the Federal Reserve System, August 27, 2007.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. E7-17191 Filed 8-29-07; 8:45 am]

**BILLING CODE 6210-01-S**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. E7-16882) published on page 49009 of the issue for Monday, August 27, 2007.

Under the Federal Reserve Bank of Richmond heading, the entry for Virginia Community Capital, Inc., Christiansburg, Virginia, is revised to read as follows:

**A. Federal Reserve Bank of Richmond** (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *Virginia Community Capital, Inc.*, which is currently operating as a Community Development Financial Institution; to become a bank holding company by acquiring 100 percent of the voting shares of Community Capital Bank of Virginia, both of Christiansburg, Virginia.

In connection with this application, Applicant also has applied to continue to engage in lending and community development activities, pursuant to sections 225.28(b)(1), (b)(12)(i), and (b)(12)(ii) of Regulation Y.

Comments on this application must be received by September 21, 2007.

Board of Governors of the Federal Reserve System, August 27, 2007.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. E7-17192 Filed 8-29-07; 8:45 am]

**BILLING CODE 6210-01-S**

## GENERAL SERVICES ADMINISTRATION

### Office of Small Business Utilization; Small Business Advisory Committee

#### Renewal of the Small Business Advisory Committee

**AGENCY:** Office of Small Business Utilization, GSA.

**ACTION:** Notice.

**SUMMARY:** Under the provisions of the Federal Advisory Committee Act of 1972, (5 U.S.C. Appendix, as amended), the Sunshine in the Government Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.65, the U.S. General Services Administration gives notice that it intends to renew the Small Business Advisory Committee (SBAC), as a discretionary Federal advisory committee.

The Office of Small Business Utilization (OSBU) has responsibility for overseeing the General Services Administration's (GSA) best efforts to achieve the small business procurement goals set by the Small Business Administration (SBA). Several procurement preference program goals (HUBZone, Service-Disabled Veteran, Women-Owned) have proven to be difficult for GSA and the Federal government as a whole to reach. Other procurement issues such as subcontracting, size standards, and availability of small manufacturers, impact the government beyond procurement goals.

As the Federal government's primary contracting agency, GSA's procurement practices and policies to a large extent affect all other Federal agencies. The GSA Small Business Advisory Committee (SBAC) was established by the OSBU to solicit the ideas and experience of association executives and small business owners in the hopes that their recommendations would serve to make the GSA small business program more effective in the future, and in turn, the entire Federal government's program.

Committee members will represent a cross-section of various socio-economic groups and chambers of commerce. One member will be appointed from a chamber of commerce from each of the following socio-economic groups: African American, Asian American / Pacific Islander, Hispanic, Native American / Alaska Native, Veteran / Service-Disabled Veteran, and Women-owned businesses. Additional members may be selected based on their expertise in government contracting, doing business with the Federal government,

and small business knowledge in general.

**FOR FURTHER INFORMATION CONTACT:**

Aaron Collmann, Room 6029, GSA Building, 1800 F Street, NW., Washington, DC 20405 (202) 501-1021 or email at [sbac@gsa.gov](mailto:sbac@gsa.gov).

**SUPPLEMENTARY INFORMATION:** This notice is published in accordance with the provisions of the Federal Advisory Committee Act (FACA) (Pub. L. 92-463).

Dated: August 27, 2007

**Michael J. Rigas**

*Deputy Associate Administrator, Office of Small Business Utilization, General Services Administration.*

[FR Doc. 07-4282 Filed 8-28-07; 12:35 pm]

**BILLING CODE 6820-34-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 2007N-0041]

**Agency Information Collection Activities; Submission for Office of Management and Budget Review; Administrative Procedures for the Clinical Laboratory Improvement Amendments of 1998 Categorization; Correction**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of May 16, 2007 (72 FR 27573). The document announced that a proposed collection of information had been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. The document was published with an error. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:** Denver Presley, Jr., Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.

**SUPPLEMENTARY INFORMATION:** In FR Doc. E7-9435, appearing on page 27573 in the **Federal Register** of Wednesday, May 16, 2007, the following correction is made:

1. On page 27574, in the third column, in the third full paragraph, the sentence "The likely respondents for this collection are Investigational New Drug Application Sponsors." is

corrected to read "The likely respondents for this collection of information are manufacturers of medical devices."

Dated: August 23, 2007.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. E7-17153 Filed 8-29-07; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Office of the Commissioner; Statement of Organizations, Functions, and Delegations of Authority**

Part D, Chapter D-B, (Food and Drug Administration), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, and 60 FR 56605, November 9, 1995, 64 FR 36361, July 6, 1999, and in pertinent part at 57 FR 54239) is being amended to reflect the restructuring of the Office of the Commissioner (OC), Food and Drug Administration (FDA). This reorganization includes the establishment of four Deputy-level offices within the Office of the Commissioner, the changes are as follows:

I. Under Part D, Food and Drug Administration, delete the Office of the Commissioner (DA) in its entirety and replace with the following:

*DA.10 Organization.* The Food and Drug Administration (FDA) is headed by the Commissioner, Food and Drug and includes the following organizational units:

Office of the Commissioner (DA), Office of the Chief Counsel (DAA), Office of the Chief of Staff (DAB), Office of International and Special Programs (DAL), Office of Operations (DAM), Office of Policy, Planning and Preparedness (DAH), Office of Scientific and Medical Programs (DAE).

*DA.20 Functions*

A. *Office of the Commissioner D(A)*—The Office of the Commissioner (OC) includes the Commissioner and Deputy Commissioner who are responsible for the efficient and effective implementation of FDA mission.

B. *Office of the Chief Counsel (DAA)*—The Office of the Chief Counsel (OCC) is also known as the Food and Drug Division, Office of the General Counsel, Department of Health and Human Services), while administratively within the Office of the Commissioner, is part of the Office of

the General Counsel of the Department of Health and Human Services.

1. Is subject to the professional supervision and control of the General Counsel, Department of Health and Human Services (HHS), and represents FDA in court proceedings and administrative hearings with respect to programs administered by FDA.

2. Provides legal advice and policy guidance for programs administered by FDA.

3. Acts as liaison to the Department of Justice and other Federal agencies for programs administered by FDA.

4. Drafts or reviews all proposed and final regulations and Federal Register notices prepared by FDA.

5. Performs legal research and gives legal opinions on regulatory issues, actions, and petitions submitted to FDA.

6. Reviews proposed legislation affecting FDA that originates in HHS or on which Congress requests the views of the Department.

7. Provides legal advice and assistance to the Office of the Secretary on matters within the expertise of the Chief Counsel.

C. *Office of the Chief of Staff (DAB)*—The Office of the Chief of Staff (OCOS):

1. Advises and provides integrated policy analysis and strategic consultation to the Commissioner, Deputy Commissioners, Associate Commissioners, Center Directors and other FDA officials on activities and issues that affect significant agency programs, projects and initiatives. Often this function involves the most difficult problems, crisis situations and extremely complex issues of FDA.

2. Provides leadership, coordination and management of the Commissioner's priority policies and issues across the Office of the Commissioner and FDA-wide. Identifies, triages, supervises and tracks related actions from start to finish in conjunction with senior leadership across FDA.

3. Provides direct support to the Commissioner of Food and Drugs and serves as major point of contact between the FDA Centers and Offices and the Commissioner.

4. Serves as the principal liaison to HHS and coordinates and manages activities between FDA and HHS. Works with the FDA Centers and Offices to ensure assignments or commitments made related to these activities are carried out.

5. Serves as one of the Commissioner's primary strategic liaisons with staff, partners, and the community at large.

6. Manages budget and resources and provides operation oversight for the FDA's Office of Legislation, Office of the